Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients. - Wikidata - wikimedia - TriplyDB

Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients.

Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients.

http://www.wikidata.org/entity/Q33868771

about

The Interactions of Obesity, Inflammation and Insulin Resistance in Breast Cancer Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines Regulatory dendritic cells: there is more than just immune activation Relationship between obesity, adipocytokines and inflammatory markers in type 2 diabetes: relevance for cardiovascular risk prevention Methylation potential associated with diet, genotype, protein, and metabolite levels in the Delta Obesity Vitamin Study Association of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and type 2 diabetes mellitus Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance.Gp130 cytokines exert differential patterns of crosstalk in adipocytes both in vitro and in vivo.Effect of diet or diet plus physical activity versus usual care on inflammatory markers in patients with newly diagnosed type 2 diabetes: the Early ACTivity in Diabetes (ACTID) randomized, controlled trial.The gp130 receptor cytokine family: regulators of adipocyte development and function.Human resistin: found in translation from mouse to man Tetrapleura tetraptera spice attenuates high-carbohydrate, high-fat diet-induced obese and type 2 diabetic rats with metabolic syndrome features Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns.Assessing the evidence: Exploring the effects of exercise on diabetic microcirculation.Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?Increased Gustatory Response Score in Obesity and Association Levels with IL-6 and Leptin.Triiodothyronine modulates the expression of leptin and adiponectin in 3T3-L1 adipocytes.The IL-6 Paradox: Context Dependent Interplay of SOCS3 and AMPK.Lipotoxicity of palmitic Acid on neural progenitor cells and hippocampal neurogenesis.Adipokines, oxidized low-density lipoprotein, and C-reactive protein levels in lean, overweight, and obese portuguese patients with type 2 diabetes.Oncostatin m is produced in adipose tissue and is regulated in conditions of obesity and type 2 diabetes.Effects of exercise on inflammation markers in type 2 diabetic subjects.Oncostatin m modulation of lipid storage.Postnatal overfeeding leads to obesity and exacerbated febrile responses to lipopolysaccharide throughout life.Incidence and correlated factors of beta cell failure in a 4-year follow-up of patients with type 2 diabetes: a longitudinal analysis of the BETADECLINE study.Adipokine Profile in Patients with Type 2 Diabetes Depends on Degree of Obesity.Gastric bypass and sleeve gastrectomy: the same impact on IL-6 and TNF-α. Prospective clinical trial.The influence of level of spinal cord injury on adipose tissue and its relationship to inflammatory adipokines and cardiometabolic profiles.Neurogenic obesity and systemic inflammation following spinal cord injury: a review.Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease.Relation between C-reactive protein and impaired fasting glucose in obese subjects.Chemerin as biomarker for insulin sensitivity in males without typical characteristics of metabolic syndrome.IL-6, TNF-α, and IL-10 levels/polymorphisms and their association with type 2 diabetes mellitus and obesity in Brazilian individuals.

P2860

Q26777775-E0882C9C-57B0-439D-AD69-241E9AB7876A Q27001148-8C2623AB-5809-4E16-B69F-EAA3F598D909 Q28388235-D2572DF7-CB8B-43E3-A3F9-1DBBF881C3C1 Q33627732-54F4228F-8D93-4433-A476-3D801651373E Q33632915-F2D80D1A-EB0A-4094-9811-AFBC8B4FE8E7 Q34256560-D51A9AC0-AC85-4955-9333-A77E23CBD1B2 Q34281793-46E10C4B-1FC5-4596-BC98-9256C116318C Q34827533-61D687E9-0D54-40AB-95E4-2A888A0F05B7 Q35021892-EA2F2967-DB52-4CBF-8388-05B3D6F10C14 Q35059389-66245211-1B86-4971-8CBD-B66435463581 Q35087560-26E60722-4891-44FA-AF05-A038CB3B458A Q35663252-CA7DE448-96A4-4106-9386-485C8A6A48C8 Q35829203-73905C69-CD6D-4BD4-8BFE-A43FDBAFA0DD Q36170520-A247D03D-5B8D-4AFE-B677-A133D8A7C586 Q36502629-8BAFC374-D2DC-400C-B763-F3480E00AF30 Q37054133-9A158840-FFBE-4D43-AD6B-812DDECB6E76 Q37098564-A5E3EB73-F3DD-4F5A-B0AF-88AB7B30C58C Q37309992-9289FC44-C195-4082-AF8A-EE647C63E5C1 Q37326225-EB5C567D-CF1C-4D3C-BFDD-6C1C70841510 Q37515305-B8219651-B39F-4B50-838A-CD9C8E8E6B20 Q37554810-48332579-D15B-408C-9F61-C0D775B629A1 Q37856870-7F98CB8C-FA2F-4C3D-ADD4-C38523D4CC08 Q38358416-967C9DE5-D58A-4ECF-9C56-AA6F2C8EEA3E Q40302454-28AAE984-6BF2-4E18-9FFE-7DBD34BFB26A Q40747617-8055A5AD-777D-4555-A7EB-1974DF468244 Q42616529-AA28DCDB-EDE8-4360-B656-D5EBADFF6254 Q45342050-46ACB46F-389A-4509-A824-0F9C3961E82B Q48010138-BB155DAA-B270-48C6-9C1F-8548F57D4A7B Q48321642-4B78AD49-EED2-42DB-97E6-57E9F6B24838 Q51268571-4EF62DB5-82DC-4E51-A8B4-1CEEC1510612 Q51355400-CF1D8FF4-A96A-42F5-9A0A-FC07C5A5409C Q51361015-CE3E433D-9804-424B-A987-DE840C7ABF38 Q54127558-1C31DAD5-58D0-4E6A-8A1F-78823BA37C02

P2860

Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients.

http://www.wikidata.org/entity/Q33868771

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Plasma adipokine and inflammat ...... ese, type 2 diabetes patients.

@ast

Plasma adipokine and inflammat ...... ese, type 2 diabetes patients.

@en

type

label

Plasma adipokine and inflammat ...... ese, type 2 diabetes patients.

@ast

Plasma adipokine and inflammat ...... ese, type 2 diabetes patients.

@en

prefLabel

Plasma adipokine and inflammat ...... ese, type 2 diabetes patients.

@ast

Plasma adipokine and inflammat ...... ese, type 2 diabetes patients.

@en

P1433

Q33868771-667B085D-D8AD-410A-A63A-B50ADC82E229

P1476

Q33868771-2D9ED9FE-6A54-49EF-8CBE-8ACE850919D1

P2093

Q33868771-1D15B6E0-DC33-48ED-85F4-FCEDC8AB1F59

Q33868771-3B8E2DDE-5455-4BB3-B14D-19AFC836166D

Q33868771-621C4438-C989-4143-A1C2-4662C4A38241

Q33868771-975DAB40-7204-4EDC-BE10-7D5411897F5A

Q33868771-9F70C886-C97D-47B9-8D60-28F4AEA46A8C

Q33868771-9FF3D960-83D9-4315-B165-04189C9A0C28

Q33868771-DB47362B-3B36-426E-876A-D65ABFFAE798

Q33868771-F658A03C-6050-4DD6-BD87-0A655A215632

P2860

Q33868771-019352BB-0F6D-48E8-8F18-464E73646F72

Q33868771-0B88DDB7-5417-4E86-BF90-4A316DF60AA4

Q33868771-0D2D09EE-CB96-49D8-87FB-4693BF31396A

Q33868771-11F25607-495C-4BD9-B84E-39A109634339

Q33868771-182DA850-E1FD-41E3-8B94-7232AF941D97

Q33868771-1FAC9F1E-F4CF-4C6E-962A-2F471492760A

Q33868771-20FB8FEA-D1B5-4C73-8197-A42A79FDDFFA

Q33868771-244C635C-D9AC-4773-8D26-6257D13819E5

Q33868771-291F031B-87D7-4767-90A4-978ABD7FECFB

Q33868771-2E3D75EB-F62B-4C92-9068-0A4175974E5B

P2888

Q33868771-429DD428-EC9F-4C62-A00B-9BE24ACE7BFE

P304

Q33868771-5C013B15-8E2E-4DF7-9179-2C7BAC5C576E

P31

Q33868771-EA32692D-C1F2-456E-A67B-8E2FA7D251BD

P356

Q33868771-BBA8FA69-3F28-4853-BC99-7E0FADF31197

P433

Q33868771-9E59A380-5362-4DFB-903F-67DA4C621E80

P478

Q33868771-6CC3F368-5F11-4D1B-A822-53492AD9CA2C

P577

Q33868771-E2EE2EF4-BD9D-4011-93FB-0B3495F598FB

P5875

Q33868771-66A50DE8-353C-4E21-B242-5797EDF8F73D

P698

Q33868771-94C97318-4099-496C-A8BD-54D90580DDB0

P921

Q33868771-1ABFC997-F53B-4056-A15E-42E2B7444986

Q33868771-330E2C73-9091-405C-9EF0-6DA5FE3B8123

P932

Q33868771-ADC86BC2-D825-4376-9E3B-7D25A1295B02

P356

S00421-010-1362-5

P1433

European Journal of Applied Physiology

P1476

Plasma adipokine and inflammat ...... ese, type 2 diabetes patients.

@en

P2093

Annelies Mullens

http://www.w3.org/2001/XMLSchema#string

Dominique Hansen

http://www.w3.org/2001/XMLSchema#string

Luc J C van Loon

http://www.w3.org/2001/XMLSchema#string

Luk Corluy

http://www.w3.org/2001/XMLSchema#string

Milou Beelen

http://www.w3.org/2001/XMLSchema#string

Paul Dendale

http://www.w3.org/2001/XMLSchema#string

Richard A M Jonkers

http://www.w3.org/2001/XMLSchema#string

Romain Meeusen

http://www.w3.org/2001/XMLSchema#string

P2860

International physical activity questionnaire: 12-country reliability and validity

Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects.

Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men.

Adipose development: from stem cell to adipocyte.

Recent advances in the relationship between obesity, inflammation, and insulin resistance.

Role of body fat distribution and the metabolic complications of obesity.

Adipocytokines and the metabolic complications of obesity.

Insulin resistance -- the role of ethnicity: evidence from Caucasian and African cohorts.

Effects of exercise on adipokines and the metabolic syndrome.

Adipogenic risk factor differences between Korean and white adults--potential role of plasma free fatty acid and adiponectin.

P2888

s00421-010-1362-5

P304

397-404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00421-010-1362-5

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41405946

http://www.w3.org/2001/XMLSchema#string

P698

20131064

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2874484

http://www.w3.org/2001/XMLSchema#string